Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders

This study has been completed.
Sponsor:
Collaborator:
BioMarin Pharmaceutical
Information provided by (Responsible Party):
Richard Frye, Arkansas Children's Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01141595
First received: June 8, 2010
Last updated: February 28, 2014
Last verified: February 2014

June 8, 2010
February 28, 2014
July 2010
September 2011   (final data collection date for primary outcome measure)
Preschool Language Scales [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Change in the raw score from baseline of the Preschool Language Scales over the 16 week period. The raw score was measured at baseline, 8 weeks and 16 weeks after starting treatment and the change over the 16 week period from baseline to the end of the study was calculated. There was no imputed data and the analysis was as treated. The raw score ranged from 0 to 130. Higher scores indicate better performance.
Cognitive and Metabolic Markers [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01141595 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders
Biomarkers of Central Nervous System Tetrahydrobiopterin Concentration and Response to Tetrahydrobiopterin Supplementation in Children With Idiopathic Cognitive Developmental Disorders

The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several critical metabolic functions.

SUMMARY

PURPOSE: The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several critical metabolic functions.

Procedures: Consented subjects' behavior, particularly irritability, cognitive and language function will be assessed at baseline to make sure that the subject meets the inclusion and exclusion criteria. Parents of subjects will be instructed to give the subjects 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast. Subjects will not be permitted to start any new supplement treatments during the study period but will be allowed to continue previous supplements. Subjects will be permitted to take over the counter medications or other prescription medications for acute illnesses. Evaluation of subjects will include three clinic visits for neuropsychological and clinical testing, completion of study-related questionnaires and telephone follow-up visits.

Course of Study: Subjects will be in the study for up to 16 weeks.

Enrollment: The study will enroll 20 (male and female) subjects, 2-6 years old, with delays in language and/or social development. Vulnerable populations include children. A pediatric risk assessment was completed by Ian Butler, MD with an outcome of minimum risks to subjects.

Recruitment: Subjects will be recruited when their parents present them for care at the University of Texas medically-based autism clinic.

Known Risks: For the study drug Kuvan, there have been rare associations with gastroesophageal reflux and a previous form of this compound was associated with seizures in individuals taking Levodopa concurrently. There is a risk of loss of confidentiality.

Data Safety Monitoring: A DSMB will not be formed for this study. The PI will be responsible for the data and safety of the study.

Informed Consent: A written parental informed consent form has been submitted for review and approval. There is no cost for participation, and no remuneration. Confidentiality will be maintained through the use of unique study codes.

IND#: A request for a pre-IND meeting with the FDA to discuss the possible IND exemption has been submitted.

Funding Source: This study is being funded by BioMarin Pharmaceuticals.

SCIENTIFIC PRE-REVIEW: The Clinical Research Unit Review Board Committee Scientific Advisory Committee (SAC) completed the submission with the outcome of CRU - Approved on12/10/2009.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Autism Spectrum Disorder
Drug: sapropterin dihydrochloride
Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Other Name: Kuvan®
Experimental: Kuvan®
Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Intervention: Drug: sapropterin dihydrochloride

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Children 2 years 0 months to 6 years 11 months of age will be recruited.
  2. Delay in language and/or social development with or without delays in gross and/or fine motor development.
  3. CSF BH4 level less than or equal to 30 nM/L as determined by lumbar puncture.
  4. Adaptive Behavior greater than 50 as determined by the Vineland Adaptive Behavior Scale.

Exclusion Criteria:

  1. Epilepsy / Seizure disorder as determined by medical history.
  2. Epileptiform discharges without clinical seizures.
  3. Metabolic disorder that would be a contraindication to tetrahydrobiopterin treatment.
  4. Genetic disorder
  5. Therapies that cannot be maintained at a constant level or have not been ongoing for more than 3 months as determined by medical history
  6. Prematurity
  7. Developmental delay isolated to motor delay.
  8. Current gastroesophageal reflux
  9. Current or history of liver or kidney disease
  10. Severe irritability (as determined by the aberrant behavior checklist)
  11. Drugs known to affect folate metabolism (e.g., methotrexate) and their derivatives
  12. Patients who are receiving drugs that affect nitric oxide-mediated vasorelaxation (e.g., PDE-5 inhibitors such as sildenafil, vardenafil, or tadalafil)
  13. Patients who are receiving levodopa.
Both
2 Years to 6 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01141595
HSC-MS-09-0578
Yes
Richard Frye, Arkansas Children's Hospital Research Institute
The University of Texas Health Science Center, Houston
BioMarin Pharmaceutical
Principal Investigator: Richard E Frye, MD Arkansas Children's Hospital Research Institute
The University of Texas Health Science Center, Houston
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP